CA-ATTACKIQ
13.4.2021 09:02:09 CEST | Business Wire | Press release
AttackIQ ®, the leading independent vendor of Breach and Attack Simulation (BAS) systems, today announced that Ross Brewer has been promoted to General Manager and Vice President of Europe, Middle East and Africa (EMEA) and Asia Pacific Japan (APJ) regions. In his new role, Brewer will be responsible for developing the strategy to expand AttackIQ’s presence in the regions, including delivering IT security and risk management leaders with solutions to identify gaps in their security posture more effectively and prioritize security initiatives more efficiently.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210413005210/en/
Brewer brings more than 35 years of sales and management experience with technology organizations across the globe. He previously served as strategic advisor for EMEA at AttackIQ, where he played a pivotal role in shaping the messaging and selling strategies over the last year to deliver strong growth in the financial and insurance services, oil and gas, healthcare, government, higher education, and technology sectors.
Additionally, he helped launch AttackIQ’s Academy in EMEA and APJ to provide advanced cybersecurity training, modularized curriculum, and cyberrange labs to security practitioners free of charge, in these markets. Today, more than 9,000 students in 100 countries across EMEA and APJ are continuing their cybersecurity education with AttackIQ Academy.
“CISOs around the globe recognize the importance of being adequately prepared for breaches, as the cost, complexity and frequency of cybersecurity attacks continues to exponentially increase,” said Carl Wright, Chief Commercial Officer, AttackIQ. “Ross has a proven track record of helping organizations in EMEA and APJ invest strategically in cybersecurity technology, partnerships, and practice enablement. We look forward to continuing to help security and risk leaders validate their investments and gain confidence with a threat-informed defense.”
In addition to large private and public customers throughout EMEA and APJ, including Bupa, BT, and a number of Government Ministries including Finance, Energy, Health and Sovereign Investment funds, AttackIQ has seen significant growth in the Gulf Cooperation Council (GCC) region as governments in countries like The United Arab Emirates, Kingdom of Saudi Arabia, Qatar, Oman, Kuwait and Bahrain look for cybersecurity solutions to protect their digital transformation initiatives.
As part of AttackIQ’s strategic expansion in these regions, the company signed a distribution agreement in November 2020 with Westcon-Comstor, a leading global technology distributor in the EMEA and APAC regions. Today, AttackIQ is building a presence and teams in the United Kingdom, United Arab Emirates, and Kingdom of Saudi Arabia.
“AttackIQ’s strong international growth is a direct result of its industry-leading platform, and I am excited to be joining the executive management team to continue helping organizations in these regions drive toward cybersecurity excellence,” said Brewer. “As recently noted by Gartner , breach and attack simulation is in the list of top security and risk management trends of 2021 due to its ability to help proactively identify and resolve gaps in security postures. The acceleration of c-suite leaders adopting a threat-informed defense and purple team construct with the help of AttackIQ is a direct result of leaders needing a higher level of confidence in their defensive posture.”
About AttackIQ
AttackIQ, the leading independent vendor of breach and attack simulation solutions, built the industry’s first Security Optimization Platform for continuous security control validation and improving security program effectiveness and efficiency. AttackIQ is trusted by leading organizations worldwide to plan security improvements and verify that cyberdefenses work as expected, aligned with the MITRE ATT&CK framework. The Company is committed to giving back to the cybersecurity community through its free AttackIQ Academy , open Preactive Security Exchange, and partnership with the MITRE Engenuity . For more information, visit www.attackiq.com . Follow AttackIQ on Twitter , Facebook , LinkedIn , and YouTube .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210413005210/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
